[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] # $nvss NovaSwap ($NVSS) is facing scrutiny as a trial for pelabresib may need to be rerun, potentially impacting its advancement. This news comes amidst a recent surge in social media engagements. ### About $nvss NovaSwap is a cryptocurrency project. ### Engagements: XX (24h)  [Engagements 24-Hour Time-Series Raw Data](/topic/$nvss/time-series/interactions.tsv) Current Value: XX Daily Average: XXX X Week: XX -XX% X Month: XXXXX -XX% X Months: XXXXX -XX% X Year: XXXXXX +39% 1-Year High: XXXXX on 2025-03-03 1-Year Low: X on 2025-01-09 Engagements by network (24h): X: XX ### Mentions: X (24h)  [Mentions 24-Hour Time-Series Raw Data](/topic/$nvss/time-series/posts_active.tsv) Current Value: X Daily Average: X X Week: X -XX% X Month: X -XX% X Months: XX -XX% X Year: XX +123% 1-Year High: X on 2024-12-28 1-Year Low: X on 2024-12-06 Mentions by network (24h): X: X ### Creators: X (24h)  [Creators 24-Hour Time-Series Raw Data](/topic/$nvss/time-series/contributors_active.tsv) X unique social accounts have posts mentioning $nvss in the last XX hours which is up XXX% from X in the previous XX hours Daily Average: X X Week: X -XX% X Month: X -XX% X Months: XX +43% X Year: XX +75% 1-Year High: X on 2024-12-28 1-Year Low: X on 2024-12-06 ### Top $nvss Social Posts Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "@RaajitRampal @clinadvances @doctorpemm @TaniaJain11 @Medscape @MKremyanskaya @doclucchesi @harrisoncn1 @VasNarasimhan @antengene @EricTokat @IcahnMountSinai @HealthTree @traviscooper93 @mpnadvocacy @GabyHobbs @Stemline @Blood_Cancers @SocietyofHemOnc @mpdrc @mlieducation @MDmasarova @JamesPharma @Genmab @mroliverbarnes @JFK_America @doctorpemm confirms $NVS will have to run a new trial for pelabresib assuming @VasNarasimhan still wants to advance the asset which seem unlikely at this point. h/t @CRTFund /297" [X Link](https://x.com/kinatsofrim/status/1990848863574405193) [@kinatsofrim](/creator/x/kinatsofrim) 2025-11-18T18:25Z XXX followers, XXX engagements "The hosts dive into $NVSs $12B acquisition of $RNA a major move in the muscle-targeted oligonucleotide space: It's really hard to look at $RNA and not also consider a $DYN because they are so similar says @BrianSkorney. I think $DYNs DM1 drugs are a little better than $RNAs but theyre a little behind $RNA too. And one of the knocks is that $RNA has this much larger Phase X study than the $DYN. That's more of an expansion cohort of a Phase X study but they'll both potentially be reviewed in somewhat parallel by the FDADefinitely going to be an interesting area to follow as these two platforms" [X Link](https://x.com/BiotechCH/status/1984297805809074299) [@BiotechCH](/creator/x/BiotechCH) 2025-10-31T16:33Z 15.4K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$nvss
NovaSwap ($NVSS) is facing scrutiny as a trial for pelabresib may need to be rerun, potentially impacting its advancement. This news comes amidst a recent surge in social media engagements.
About $nvss
NovaSwap is a cryptocurrency project.
Engagements: XX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XX -XX%
X Month: XXXXX -XX%
X Months: XXXXX -XX%
X Year: XXXXXX +39%
1-Year High: XXXXX on 2025-03-03
1-Year Low: X on 2025-01-09
Engagements by network (24h): X: XX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: X -XX%
X Month: X -XX%
X Months: XX -XX%
X Year: XX +123%
1-Year High: X on 2024-12-28
1-Year Low: X on 2024-12-06
Mentions by network (24h): X: X
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $nvss in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X
X Week: X -XX%
X Month: X -XX%
X Months: XX +43%
X Year: XX +75%
1-Year High: X on 2024-12-28
1-Year Low: X on 2024-12-06
Top $nvss Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@RaajitRampal @clinadvances @doctorpemm @TaniaJain11 @Medscape @MKremyanskaya @doclucchesi @harrisoncn1 @VasNarasimhan @antengene @EricTokat @IcahnMountSinai @HealthTree @traviscooper93 @mpnadvocacy @GabyHobbs @Stemline @Blood_Cancers @SocietyofHemOnc @mpdrc @mlieducation @MDmasarova @JamesPharma @Genmab @mroliverbarnes @JFK_America @doctorpemm confirms $NVS will have to run a new trial for pelabresib assuming @VasNarasimhan still wants to advance the asset which seem unlikely at this point. h/t @CRTFund /297"
X Link @kinatsofrim 2025-11-18T18:25Z XXX followers, XXX engagements
"The hosts dive into $NVSs $12B acquisition of $RNA a major move in the muscle-targeted oligonucleotide space: It's really hard to look at $RNA and not also consider a $DYN because they are so similar says @BrianSkorney. I think $DYNs DM1 drugs are a little better than $RNAs but theyre a little behind $RNA too. And one of the knocks is that $RNA has this much larger Phase X study than the $DYN. That's more of an expansion cohort of a Phase X study but they'll both potentially be reviewed in somewhat parallel by the FDADefinitely going to be an interesting area to follow as these two platforms"
X Link @BiotechCH 2025-10-31T16:33Z 15.4K followers, XXX engagements